COMMENTARY

Generic Industry’s Tactic to Thwart 50% Pricing Rule Draws Mixed Reviews

January 18, 2016

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The tactic selected by the Japan Generic Medicines Association (JGA) to prevent the government from introducing a 50% pricing rule for first generics has received mixed reactions from health ministry bureaucrats and industry insiders. Some at the Ministry of Health,…

To read the full story

JGA Takes Sincerely 50% Pricing Rule for First Generics, There’s Limitation to Data Collection: Chief
January 13, 2016

COMMENTARY

Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise
December 22, 2025
FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed
December 9, 2025
MOF Autumn Proposals Signal a Shift from Drug Pricing to Cost-Sharing Reform
November 17, 2025
Japan’s Trading Houses Gain Ground in Pharma, Rewriting the Industry Playbook
November 10, 2025
The Price of Stability: Who Bears Japan’s Drug Distribution Burden?
October 27, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests

By Takashi Ebisawa

The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…

COMMENTARY

Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise

By Koji Shimomura

Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…